Mod GRF 1-29 & GHRP-2 Blend (10mg)


Size: 10mg
Contents: CJC-1295 NO DAC (Mod GRF 1-29) 5mg, GHRP-2 5mg
Form: Lyophilized powder
Purity: >99%

FREE Shipping on $200+ orders

FREE Bacteriostatic Water (30ml) on $200+ orders

Discount per Quantity

5 - 85%$62.70
9 +10%$59.40
SKU: P-MODGRFGHR2-10 Categories: , Tags: , ,


GHRP-2 and Modified GRF 1-29 peptides are synthetic peptides developed to aid in the body’s synthesis, secretion, and regulation of growth hormones. When taken together as a blend, these peptides appear to exert synergistic effects, providing additional health benefits to the body. GHRP-2 is a synthetic peptide similar to ghrelin, a naturally occurring peptide produced in the human body.(1) Ghrelin is a peptide containing 28 amino acids that help to regulate growth hormones, appetite, and heal wounds.(2) Modified GRF 1-29 (or Mod GRF 1-29) is an artificial peptide analogous to the naturally occurring growth hormone-releasing hormones (GHRH). Structurally similar to GHRH, the peptide contains a chain of 29 amino acids and is slightly modified for durability via the substitution of a four amino acid-chain.(3) These two peptides have been studied for their potential to stimulate the pituitary cells, triggering the secretion of growth hormones. GHRP-2 appears to have additional modes of action where (i) it may bind with growth hormone release factor (GRF) receptors, (ii) may act on calcium channels and stimulate growth hormone release, and (iii) may trigger cAMP pathway and protein kinase C, which in turn may stimulate growth hormone release.(4)

Chemical Makeup(3,5)

Molecular formula:
Modified GRF 1-29 peptide: C152H252N44O42
GHRP-2: C45H55N9O6

Molecular weight:
Modified GRF 1-29 peptide: 3367.9 g/mol
GHRP-2: 818.0 g/mol

Other known titles
Modified GRF 1-29 peptide: 

  • CJC 1295 Without DAC
  • Mod GRF (1-29)


  • Pralmorelin
  • Growth hormone-releasing peptide-2


Modified GRF 1-29 & GHRP-2 Peptide Blend and Pharmacological Effects

Several studies(6) have been carried out on animals to understand the various pharmacological effects of this class of peptides promoting growth hormone synthesis and release. According to researchers, the administration of the peptides in both guinea pigs and rabbits did not result in any profound effect on the central nervous systems. The only change seen was an increase in the motility rate of the isolated ileum of rabbits and increased muscle contractions in the isolated ileum of the guinea pigs. No other effects were observed on the kidneys, respiratory, gastric, and blood systems. As per Furuta S et al., these results suggest that the peptide “has no serious general pharmacological effects at dose levels showing GH-releasing activity in the experimental animals. Therefore, it is concluded that the peptide will be a useful drug for diagnosing serious GH deficiency and treating short stature.”(6)

Modified GRF 1-29 & GHRP-2 Peptide Blend and Appetite

A clinical trial(7) was carried out in which seven healthy male volunteers participated. The participants in the trial were divided into two groups – one of which was administered with the peptide, and the others were administered with saline solution for approximately 5 hours. After peptide administration, all candidates were taken to buffet-style meals to measure their food intake.  The peptide-administered candidates ate approximately 35% more than the saline-treated group, with each candidate exhibiting increased appetite when measured against their body weight. Moreover, the concentration of growth hormone also appeared to increase significantly in the peptide-treated volunteers.  These results indicate a possibility that one of the additional effects of the peptide blend may be increased food intake and appetite. 

General Research in Growth Hormone Secretagogues (GSHs), Growth Hormone Releasing Peptides (GHRPs)

The key objective of these studies(8) was to evaluate how safe and effective growth hormone secretagogues (GSHs) and growth hormone-releasing peptides (GHRPs) are amongst healthy volunteers. As part of the study, numerous volunteers were monitored for physiological changes after being subjected to peptide administration. After completing this study, the results demonstrated that these peptides appeared to yield an increased growth rate in children, increased appetite, and increased lean mass in adults. In obese candidates, these peptides appeared to stimulate a reduction in bone turnover, increased lean mass, and improved sleep cycle.  These recent studies indicate that humans may tolerate these peptides; however, some concerns must be further examined. The researchers stated that these peptides appear to “increase lean body mass, reduce fat mass, increase exercise tolerance and maximum oxygen uptake, enhance muscle strength, and improve linear growth. Long-term studies of GH administration offer conflicting results regarding its safety, which has led to strict FDA criteria for GH use.”(8)

Modified GRF 1-29 & GHRP-2 Peptide Blend and Growth Hormone Deficiency

Since 2000, several clinical studies have been conducted on candidates possessing growth hormone deficiency. Adults administered with peptides stimulating growth hormone release showed that these peptides might produce their effects in two ways, including (i) stimulating the pituitary gland to release growth hormones and (ii) acting on the arcuate nucleus of the hypothalamus. While these peptides, including GHRP-2 and Modified GRF 1-29, appeared to yield high concentrations of growth hormones, it remains to be seen how they work in the body. In addition, these studies suggested that these peptides may impact food intake, heart tone, and sleep cycle via receptor-specific agonistic effects.(9)

In a study focusing on children, six growth hormone-deficient participants facing growth failure were subjected to different doses of growth hormone-stimulating peptides for eight months.(10) All children were monitored for any significant rise in growth hormone levels and toxicity levels during this period.  Throughout the study, there appeared to be a steep rise in the levels of growth hormones in all children for the duration of the study and a little time after. As per V Mericq et al., the study suggested that the peptides were “well tolerated and [may] stimulate GH secretion.”

Modified GRF 1-29 & GHRP-2 Peptide Blend and Body Hormones

In one clinical study(11), the primary objective was to understand the effects of peptide administration on growth hormones, cortisol, prolactin, and adrenocorticotropic hormone (ACTH) levels in men. All volunteers were divided into two groups based on their age – the first group had six adults aged between 22 and 27 years, and the second group had 6 adults aged between 66 and 73 years. Both groups were administered with growth hormone release stimulating peptides like Mod GRF 1-29 & GHRP-2. While the growth hormone levels increased in both groups, the younger group was observed to have a significant increase compared to the elderly volunteers. These hormones also appeared to stimulate increased levels of ACTH and cortisol hormones and a mild increase in prolactin levels.  The results supported the hypothesis that these peptides may have profound hormonal secretion capabilities in both elderly and young male candidates. Scientific studies are ongoing to determine the effects of peptide blends in humans. Currently, the blend available in the market is for educational and research purposes only. 



  1. Garcia JM, Merriam GR, Kargi AY. Growth Hormone in Aging. [Updated 2019 Oct 7]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): 
  2. Phung LT, Sasaki A, Lee HG, Vega RA, Matsunaga N, Hidaka S, Kuwayama H, Hidari H. Effects of the administration of growth hormone-releasing peptide-2 (GHRP-2) orally by gavage and in feed on growth hormone release in swine. Domest Anim Endocrinol. 2001 Jan;20(1):9-19. 
  3. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 91976842, CJC1295 Without DAC.
  4. Roh SG, He ML, Matsunaga N, Hidaka S, Hidari H. Mechanisms of action of growth hormone-releasing peptide-2 in bovine pituitary cells. J Anim Sci. 1997 Oct;75(10):2744-8. doi: 10.2527/1997.75102744x. PMID: 9331879. 
  5. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 6918245, Pralmorelin.
  6. Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumi M. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):868-80. doi: 10.1055/s-0031-1297042. PMID: 15646371.  
  7. Laferrère, Blandine et al. “Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.” The Journal of clinical endocrinology and metabolism vol. 90,2 (2005): 611-4. 
  8. Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004 
  9. Rogério G. Gondo et al, Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 7, 1 July 2001, Pages 3279–3283,  
  10. Mericq V, Cassorla F, Salazar T, Avila A, Iñiguez G, Bowers CY, Merriam GR. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab. 1998 Jul;83(7):2355-60.  
  11. Emanuela Arvat, Lidia Di Vito, Barbara Maccagno, Fabio Broglio, Muni F Boghen, Romano Deghenghi, Franco Camanni, Ezio Ghigo, Effects of GHRP-2 and Hexarelin, Two Synthetic GH-Releasing Peptides, on GH, Prolactin, ACTH and Cortisol Levels in Man. Comparison with the Effects of GHRH, TRH and hCRH, Peptides, Volume 18, Issue 6, 1997, Pages 885-891, ISSN 0196-9781, 


NOTE: These products are intended for laboratory research use only. Mod GRF 1-29 & GHRP-2 blend for sale is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.